Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

CAR T-Cell Agents Offer Efficacy in Lymphoma, But Additional Approaches Are Needed to Overcome Resistance

May 17th 2024

Sattva S. Neelapu, MD, discusses the current standing of CAR T-cell therapies in the treatment paradigm in lymphoma.

Leveraging Managed Service Organizations to Provide More Affordable, Personalized Cancer Care

May 17th 2024

To combat the rising costs of cancer care, clinicians are partnering with managed service organizations to handle the business aspects of practice.

Pellini Discusses Immunotherapies and Current Limitations of ctDNA in Perioperative NSCLC

May 16th 2024

Bruna Pellini, MD, highlights the multiple immunotherapies currently available for patients with NSCLC in the perioperative setting and elucidates ctDNA’s role in the treatment paradigm.

Advances in MRD Testing Help Guide Optimal Colorectal Cancer Therapy

May 10th 2024

During an OncLive Peer Exchange, a panel of expert clinicians in CRC discussed studies seeking to further define the role of MRD testing in CRC.

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist

May 6th 2024

No significant difference in time to treatment was found between White and Black patients with bladder cancer, but there remained a difference in treatment outcomes.

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

May 6th 2024

Darolutamide uptake in metastatic hormone-sensitive prostate cancer has become routine both in doublet and triplet regimens in community urology practices.

TAR-210 Demonstrates Preliminary Efficacy in FGFR-Altered Non–Muscle-Invasive Bladder Cancer

May 5th 2024

TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.

UGN-102 With/Without TURBT Produces Similar DOR and DFS in Newly Diagnosed and Recurrent NMIBC

May 5th 2024

UGN-102 with/without TURBT displayed meaningful and similar DFS and DOR rates in newly diagnosed and recurrent low-grade intermediate-risk NMIBC.

Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC

May 4th 2024

Enzalutamide alone and with leuprolide led to greater rates of undetectable PSA levels vs leuprolide alone in castration-sensitive prostate cancer.

TAR-200 Leads to Durable Responses in Bacillus Calmette–Guérin-Unresponsive NMIBC

May 3rd 2024

TAR-200 displayed a high complete response rate in Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer.

Frontline Acalabrutinib Plus Chemoimmunotherapy Elicits Meaningful Survival Benefit in MCL

May 2nd 2024

Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.

Adjuvant Multipeptide Vaccine Combination Prolongs Survival in Melanoma

May 2nd 2024

A multipeptide vaccine combination approach with 12MP plus 6MHP vs 12MP plus tet extended overall survival in patients with stage IIB to IV melanoma.

Immunogenomics Demonstrate Predictive Capability to Immunotherapy Resistance in Uveal Melanoma

May 1st 2024

Immunogenomic information displays predictive capability in terms of immunotherapy resistance in metastatic uveal melanoma.

Tumor Intrinsic Subtype Affects Relationship Between pCR and EFS in ERBB2+/HER2+ Early Breast Cancer

April 30th 2024

Tumor intrinsic subtype impacted the association between pCR and EFS after chemotherapy and ERBB2/HER2 blockade in ERBB2/HER2-positive early breast cancer.

ASCO Updates Advanced HCC Treatment Guideline

April 29th 2024

ASCO has announced a guideline update for systemic therapy in advanced hepatocellular carcinoma.

MRI-Guided Neoadjuvant Chemotherapy Could be Used in HR-/HER2+ Breast Cancer

April 28th 2024

MRI-guided treatment could be used to optimize the duration of neoadjuvant chemotherapy in hormone receptor-negative/HER2-positive breast cancer.

CHMP Recommends Frontline Nivolumab Plus Chemo in Unresectable/Metastatic Urothelial Carcinoma

April 26th 2024

Frontline nivolumab plus chemotherapy has been recommended for approval in unresectable or metastatic urothelial carcinoma.

DENALI Study Seeks to Prove Efficacy of Azenosertib in High-Grade Serous Ovarian Cancer

April 26th 2024

The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.

Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC

April 24th 2024

Frontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression.

International Pancreatic Cancer Screening Program Displays Practicality

April 24th 2024

The PRECEDE study demonstrated the feasibility of a large-scale early detection and prevention program for pancreatic cancer.